Restasis®
(Cyclosporine Ophthalmic Emulsion) 0.05%

MEDICARE PART D PATIENTS

9 OUT OF 10 ARE COVERED[1]

MOST MEDICARE PART D PATIENTS HAVE UNRESTRICTED ACCESS TO RESTASIS®[1,*]



*As of July 2019.[1]

Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with the applicable insurer.
Allergan® does not endorse any individual plans.
Formulary coverage comparisons are not intended to imply a comparison of efficacy, safety, therapeutic equivalence, or overall cost of care.

Indications and Usage

RESTASIS® and *RESTASIS MultiDose®* ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information

Contraindications

RESTASIS® and *RESTASIS MultiDose®* are contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

Please see additional Important Safety Information on the reverse side.

PATIENTS MAY FILL MORE MONTHS OF THERAPY WHEN PRESCRIBED A 90-DAY SUPPLY OF RESTASIS®[2]

On average, patients filling 90-day supplies have filled more months of therapy than patients filling 30-day supplies[2,*]



63%

greater average drug fill over 7 months when prescribed a 90-day supply[2,†]

†Calculation based on dispensed quantity over a 7-month study period to Medicare patients prescribed RESTASIS®.

Be sure to prescribe the correct number of single-use vials for a 90-day supply

- 180 vials of RESTASIS®

*As of April 2017.[2]

Important Safety Information (continued)

Warnings and Precautions

Potential for Eye Injury and Contamination: Be careful not to touch the container tip to your eye or other surfaces to avoid potential for eye injury and contamination.

Use With Contact Lenses: RESTASIS® and *RESTASIS MultiDose*® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS® and *RESTASIS MultiDose*® ophthalmic emulsion.

Adverse Reactions

In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see accompanying full Prescribing Information.

References: 1. Managed Markets Insights & Technology, LLC™, a trademark of MMIT Database, as of July 2019.
2. IQVIA, Allergan Brands Daily Consumption Analysis. April 2017.

Allergan an AbbVie company

Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%